J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints
OWS Leader Predicts Success
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
You may also be interested in...
The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
After the Aduhelm controversy, Biogen has another neurodegenerative disease drug which so far can only show efficacy against surrogate biomarkers – will the FDA be swayed again this time?